WHY? SUMMITS

Updated: 13 May, 2026

for the latest programe update, please download agenda on conference website

May 14 - 15, 2026

London, UK
Hilton London Olympia
380 Kensington High Street,
London W14 8NL,
United Kingdom

PPM SUMMIT LONDON 2026

Biopharma PPM in Clinical Research and Development Summit

Gold Sponsor: OnePlan

Strategic Partner: Planisware

PPM WORLD TOUR 2026

WHY? SUMMITS



WHY PPM WORLD TOUR STANDS ABOVE THE REST

Struggling with resource constraints, complex portfolios, or AI adoption?

Through visionary keynotes, practical case studies, hands-on workshops, and peer driven roundtables, you´ll gain not only the frameworks and tools to deliver results but also the strategic connections that will power your projects forward.

*"This conference delivers **exactly what you need** without the unnecessary fluff of other events"*

THE PPM WORLD TOUR:

- Brings together a curated group of Senior-Level Decision Makers, all facing challenges similar to yours.
- Offers carefully crafted sessions led by speakers with proven experience and insights that inspire action.
- Ensures all sponsors provide relevant, tested solutions aligned with attendees' needs and interests.
- Features tailored networking programs to connect you with the people who truly matter to your goals.

MOST CONFERENCES:

- Cater to attendees with varying priorities and experience levels, creating a lack of focus
- Feature speakers with outdated presentations that fail to provide anything new or valuable
- Feature hidden sales pitches as presentations, offering no relevance to the audience
- Rely on chance for attendees to meet the right connections

CONFERENCE OVERVIEW:

- **Strategy to Submission**
- **Schedule and Critical Paths in Trials**
- **Risk, Quality, and Inspection Readiness**
- **Cost, Contract, and Vendor Oversight**
- **High-Performance Project Teams: Culture, Collaboration, and Technology**
- **PMO & Portfolio: From One-Person Shop to Enterprise Engine**

TESTIMONIALS

I just wanted to take a moment to extend my sincere gratitude for the fantastic conference you organized. It was an absolute pleasure to attend, and I thoroughly enjoyed being part of the panel discussion. The entire event was incredibly insightful, and I walked away with a wealth of knowledge and new perspectives. Your efforts in putting together such a well-structured and engaging conference are truly commendable. Thank you once again for the opportunity, and I look forward to future events.

★★★★★

Dr. Therese Triemer
Associate Director Process Innovation
Novartis

We would like to extend our gratitude for the opportunity to present our speech. It was an incredible experience to share our thoughts, ideas, and experiences with such an engaged audience. Thank you for your time, attention, and the valuable discussions that followed. We look forward to future opportunities to connect and share insights.

★★★★★

Raffaele Marranzini
Chief Executive officer
Platflow (Lean IT Consulting)

I truly enjoyed being there among others high skilled professionals! My personal thanks to everybody enabling this great discussion! I was especially delighted to touch the diversity of the clinical trials data.

★★★★★

Guna Dansone
Head of Clinical research
Olpha

We were proud to be Sponsors for the 31st European Life Sciences Project & Portfolio Management Conference in London. Two really energising days of learning and connection. Huge thanks to Why Summits for such a well-run event. The presentations, panels and workshops sparked great conversations around portfolio strategy, governance, risk and innovation across the sector. Most of all, it was fantastic to reconnect with familiar faces and meet new Life Sciences leaders who share the same passion for PPM.

★★★★★

Merryn Horneman
Life Sciences Delivery Partner
Mi-GSO-PCUBED

This week, I had the privilege of presenting at the Why Summits: 26th EU Pharma and Biotech Project Program and Portfolio Management Conference. My presentation focused on the digital evolution of Pfizer Pharm Sci's global resource management model followed by a panel with Amit Arkad, EMBA, PMP on aligning people and portfolio priorities. The conference offered fascinating insights.

★★★★★

Nicola Clear
Director Pharmaceutical Sciences, Portfolio Excellence
Pfizer

Grateful for the engaging conversations and the chance to share insights with such a talented group of professionals. Looking forward to applying these learnings and continuing the dialogue on these critical subjects!

★★★★★

Rosa Arienzo
Translational Science Portfolio Manager
LifeArc

INDUSTRY PIONEERS ATTENDING FROM

CONFIRMED SPEAKERS

WHY? SUMMITS

Patrick Kamba
Executive Director, Project Management
PPD - Thermofisher Scientific

Hazel Hodgson
Director of Project Management
PPD - Thermofisher

Guna Dansone
Head of Clinical Research
Olpha

Bahadir Cakmak
Global Pipeline Director
Sandoz

Patrick Ramiah
Director of Clinical Project Delivery and Operational Excellence
Richmond Pharmacology

Jortin George
Regional Head UK& Europe
Cipla

Puja Myles
Director, Clinical Practice Research Datalink
Medicines and Healthcare products Regulatory Agency

Arijit Patra
Senior Principal Scientist
UCB

Corinne Ramos, PhD, MBA
Director, Research and Development
Aliri

Jesse Gallagher
Early Phase Risk & Compliance Lead II
Parexel

Nina Hibaile Monthe
Senior Global Project Manager
Simbec-Orion

Jignesh Rathod
Senior Director and Head of Project Management - Europe
Parexel

George Havers
Director
Trialmed

Faith Anane
Regulatory Lead
Simbec-Orion

James Rickard
Chief Scientific Officer
Richmond Research Institute

Samantha Larner
Programme Delivery Manager
Medicines and Healthcare products Regulatory Agency

Matt Stevenson
Engagement Manager, Delivery
OnePlan

Noel Kusotera
Head of Quality Assurance
Richmond Pharmacology

Simone Battaglia
Senior Manager EU PMO Immuno
Diasorin

NIGHT BEFORE THE EVENT

DAY 1

18:00 **Meet & Greet**

Get a head start on networking!

Kick off the experience with early registration and a relaxed networking session over drinks! As delegates start arriving, this is the perfect opportunity to connect, catch up with familiar faces, and meet new industry peers. Whether it's handshakes, conversations, or shared laughs, we invite you to join us in setting the stage for an inspiring event. Cheers to new connections and meaningful discussions!

CONFERENCE AGENDA

DAY 1

8:30 **Registration and Welcome Coffee**

9:00 **Chairmans Opening Address**

Patrick Kamba – Executive Director, *Project Management,* **PPD - Thermofisher Scientific**

9:10 **START WITH WHY? ICE-BREAKER SESSION**

MEET YOUR PEERS, SHARE YOUR PRIORITIES, AND SET YOUR OBJECTIVES

A short, structured icebreaker session designed to help delegates connect early, promote networking, share their priorities, and start the conference with more relevant conversations.

- Why are you attending the conference?
- What are your main challanges (in PPM/PV/etc...)
- What do you want to learn about or take away?

STRATEGY TO SUBMISSION

9:30 **KEYNOTE**

INTEGRATING SPATIAL BIOLOGY AND BIOANALYSIS TO ENABLE PREDICTIVE DRUG DEVELOPMENT

As oncology programs become increasingly complex, there is a growing need to move beyond traditional plasma PK and descriptive biomarkers toward more predictive, tissue-level insights. This session will explore how integrating quantitative bioanalysis (e.g., LC-MS/MS) with spatial approaches (such as imaging mass spectrometry and tissue-based biomarker profiling) enables a more comprehensive understanding of drug exposure, target engagement, and biological response within the tumor microenvironment. The objective is to demonstrate how these integrated strategies can support more informed decisions and reduce uncertainty in early clinical development.

Key Takeaways

- Aligning bioanalytical and biomarker strategies with clinical decision points
- Understanding drug distribution and activity directly at the tissue level
- Linking exposure, target engagement, and pharmacodynamic response
- Enabling more confident go/no-go decisions through integrated data

Corinne Ramos, PhD, MBA, *Director, Research and Development,* **Aliri**

10:00 **PANEL DISCUSSION**

GREENLIGHTING WITH CONFIDENCE - WHAT MUST BE IN THE PACK?

A multi stakeholder discussion on what truly convinces governance to approve a phase gate. Leaders from Clinical Development, Regulatory Strategy, Chemistry Manufacturing and Controls, Biostatistics, Portfolio and Finance, and a Program or Project Manager compare evidentiary bars, trade offs, and accountability so you hear the tensions, not a checklist.

- **Regulatory view:** what makes a Regulatory Target Product Profile credible for locking design and label intent, and which precedents or guidance matter most
- **Value versus risk:** how Portfolio and Finance with Biostatistics balance Probability of Success and expected Net Present Value against late Investigational Medicinal Product or Chemistry Manufacturing and Controls uncertainty
- **Operations reality check:** when Chemistry Manufacturing and Controls or Technical Operations should request a delay due to stability, comparability, or relabel risk, and when Clinical should accept risk to keep timeline
- **Data readiness and last mile handoffs:** what must be true from Data Cut Off to Clinical Study Report to Common Technical Document for a believable submission clock
- **Governance and ownership:** which Responsible Accountable Consulted Informed pattern actually speeds decisions, and the change control triggers that a Project Manager must escalate
- **Executive view:** the essential signals for a weekly portfolio dashboard including First Patient First Visit, Last Subject Last Visit, Database Lock variance, risk heat, spend versus plan, and open Health Authority queries

Patrick Ramiah, *Director of Clinical Project Delivery and Operational Excellence,* **Richmond Pharmacology**

Faith Anane, *Regulatory Lead,* **Simbec-Orion**

CONFERENCE AGENDA

DAY 1

10:30 **CASE STUDY**

TRANSFORMING PROJECT PORTFOLIO MANAGEMENT AT DIASORIN: A STRATEGIC JOURNEY TOWARD GLOBAL PPM EXCELLENCE

Diasorin, a global leader in laboratory diagnostics, embarked on a strategic initiative to advance excellence in project and portfolio management and elevate decision-making across the enterprise. This session shares how DiaSorin implemented a PPM solution across Product Development including Clinical operations, onboarding enterprise resources globally through a phased rollout. Learn how two tailored project frameworks, unified workload management, and meaningful visualizations now deliver a single source of truth for portfolio oversight and explore the roadmap ahead encompassing end-to-end strategy execution.

Simone Battaglia, *Senior Manager EU PMO Immuno,* **Diasorin**

11:00 **Morning Coffee and Networking**

SCHEDULE AND CRITICAL PATH IN TRIALS

11:30 **KEYNOTE**

TRANSFORMING STRATEGY INTO EXECUTION: ONEPLAN FOR LIFE SCIENCES PORTFOLIO AND PROGRAM SUCCESS

In today's regulated Life Sciences environment, effective execution across R&D and Technical Operations is critical to accelerating innovation and maximizing portfolio value. This session shows how OnePlan translates strategy into measurable outcomes using strategic imperatives, objectives, and OKRs.

See how strategy cascades into aligned programs and projects with visibility into milestones, resources, and dependencies. OnePlan delivers real time insights to prioritize investments, adapt to change, and accelerate delivery while maintaining regulatory and operational discipline.

Matt Stevenson- Engagement Manager, *Delivery,* **OnePlan**

12:00 **PANEL DISCUSSION**

THE REAL CRITICAL PATH IN TRIALS

Clinical Operations, Biostatistics, Data Management, Country start up, and a Program or Project Manager debate what truly drives dates and what project managers should escalate.

- **Protocol to Work Breakdown Structure (WBS):** how to size visits, monitoring, and analysis so the baseline is credible.
- **Recruitment reality:** choosing the country and site mix and knowing when to resequence.
- **Data discipline:** Data Cut Off (DCO) to Database Lock (DBL) controls that protect quality and dates.
- **Investigational Medicinal Product (IMP) readiness:** when supply becomes the driver and how to recover.
- **Executive view:** the five schedule signals leadership must see weekly, including First Patient First Visit (FPFV), Last Subject Last Visit (LSLV), DCO and DBL variance, and risk trend.

Arijit Patra, *Senior Principal Scientist,* **UCB**
Nina Hibaile Monthe, *Senior Global Project Manager,* **Simbec-Orion**

RISK AND QUALITY AND INSPECTION READINESS

12:30 **CASE STUDY**

RBQM THAT TRIGGERS ACTION, NOT REPORTS

A sponsor leader shows how a study risk assessment became a living Risk Management Plan (RMP) with Quality Tolerance Limits (QTLs) and Key Risk Indicators (KRIs) that drive timely actions and tan dup in inspections.

- Set QTLs from critical to quality factors and align them to KRIs and central monitoring.
- Turn signals into actions with owners, due dates, and effectiveness checks.
- Use TMF health as a leading indicator for quality and inspection readiness.
- Run an issue to CAPA flow that survives Food and Drug Administration (FDA) and European Medicines Agency (EMA) scrutiny.

Guna Dansone, *Head of Clinical Research,* **Olpha**

13:00 **Networking Luncheon**

14:00 **PANEL DISCUSSION**

INSPECTION READY EVERY DAY

Quality Assurance, Clinical Operations, Data Management, the TMF lead, and a Program or Project Manager compare what inspectors really test and how PMs keep control.

- Choosing QTLs, when they trigger, and how to justify thresholds.
- Which KRIs matter and how central monitoring complements on site work.
- TMF that tells the trial story; metrics inspectors ask to see.
- CAPA effectiveness and when to escalate repeat deviations.
- Sponsor oversight of contract research organizations and vendors.

Hazel Hodgson, *Director of Project Management,* **PPD, Thermofisher**
Guna Dansone, *Head of Clinical Research,* **Olpha**
Jesse Gallagher, *Early Phase Risk & Compliance Lead II,* **Parexel**

14:30 **WORKSHOPS**

WORKSHOP 1: BUILD A PRACTICAL APPROACH TO APPLYING REAL-WORLD DATA ACROSS THE TRIAL LIFECYCLE WHILE MANAGING RISK AND MAXIMISING VALUE.

- Define RWD and align on key data types and terminology across participants
- Explore high-impact use cases and identify where RWD adds most value in trials
- Identify opportunity areas and prioritise where RWD can deliver impact in your work
- Assess risks and share mitigation approaches across data quality, bias, and governance
- Discuss barriers, challenges, and collaboration opportunities with peers
- Develop a practical framework to select, apply, and manage RWD use

Take home: RWD decision framework, use-case map, and risk management checklist

Samantha Larner, *Programme Delivery Manager,* **Medicines and Healthcare products Regulatory Agency**

CONFERENCE AGENDA

DAY 1

WORKSHOP 2: RISK TO RMP CLINIC

Build a practical Risk Management Plan that drives actions.

- Identify critical to quality factors and rank risks.
- Set QTL thresholds with action and communication plans.
- Create a KRI library with data sources, checks, and triggers.
- Draft an escalation ladder and effectiveness checks.

Take home: RMP template and QTL–KRI matrix.

George Havers, *Director,* **Trialmed**

15:30 **Afternoon Coffee and Networking**

16:00 **ROUNDTABLES**

ROUNDTABLE 1: MAKING THE REGULATORY TARGET PRODUCT PROFILE DECISION GRADE

Open Q and A with a Regulatory Strategy lead on turning a Regulatory Target Product Profile (RegTPP) into a design and claims lock before pivotal trials.

- Which precedents and guidances must be cited to make a RegTPP credible for our indication and regions
- How to reconcile differences between RegTPP and the Development Target Product Profile
- What minimum evidence is acceptable at the gate and what is a showstopper
- How expedited pathways change the bar and the submission clock
- How to document Health Authority feedback so governance can rely on it

George Havers, *Director,* **Trialmed**

ROUNDTABLE 2: CMC AND SUPPLY ON THE CRITICAL PATH

Deep dive with Chemistry Manufacturing and Controls and Technical Operations on Investigational Medicinal Product (IMP) readiness signals that protect gates and submissions.

- Stability, expiry, and comparability thresholds that allow a Go versus require a delay
- How relabel and country specific packaging affect First Patient First Visit, Last Subject Last Visit, and Database Lock
- What Interactive Response Technology rules prevent stock outs and overage waste
- The minimum viable CMC readiness signal to proceed at each gate
- How to surface CMC and supply risks in the executive dashboard so actions are clear

James Rickard, *Chief Scientific Officer,* **Richmond Research Institute**

ROUNDTABLE 3: CAPA THAT STICKS

Root cause analysis techniques, effectiveness criteria, when to open a CAPA versus manage an issue, and useful cycle time metrics.

Hazel Hodgson, *Director of Project Management,* **PPD, Thermofisher**

17:00 **Informal Networking**

CONFERENCE AGENDA

DAY 2

8:55 Chairmans Opening Remarks

9:00 CASE STUDY

THE USE OF REAL-WORLD DATA IN CLINICAL TRIALS

What this session will cover:

- How electronic healthcare record (EHR) data from UK primary care practice has been used to find and recruit eligible patients for clinical trials, provide follow-up data to ascertain clinical trial outcomes, support safety monitoring and for external control arms.
- Key regulatory considerations around data quality when using EHR data to support clinical trials

Puja Myles, *Director, Clinical Practice Research Datalink,* **Medicines and Healthcare products Regulatory Agency**

COST, CONTRACTS AND VENDOR OVERSIGHT

Cost plus procurement plus stakeholder control means fewer surprises. This block shows how project managers prove sponsor oversight with Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs).

9:30 PANEL DISCUSSION

PROVING SPONSOR CONTROL WITH PARTNERS

Clinical Operations, CMC and Technical Operations, Quality Assurance, Procurement and Legal, Finance, and a Program or Project Manager discuss how to stay in charge while outsourced.

- What to lock in the Master Services Agreement and the SOW to avoid ambiguity
- The few KPIs and SLAs that really predict delivery and quality
- When to open a change order versus absorb within contingency
- How to use the Quality Technical Agreement during deviations and audits
- Escalation ladders that resolve issues fast without damaging the relationshipň

Nina Hibaile Monthe, *Senior Global Project Manager,* **Simbec-Orion**
Noel Kusotera, *Head of Quality Assurance,* **Richmond Pharmacology**

HIGH-PERFORMANCE PROJECT TEAMS: CULTURE, COLLABORATION AND TECHNOLOGY

10:00 CASE STUDY

RECOVERING A FAILING PROJECT THROUGH CULTURE TRANSFORMATION

Real-life example of a pharmaceutical or biotech team that faced severe delays due to misaligned team dynamics and how leadership reshaped the culture to achieve delivery goals.

- How early warning signs of poor culture and trust were identified
- Leadership actions that restored accountability and motivation
- Lessons learned on sustaining a high-performance mindset post-crisis

Patrick Ramiah, *Director of Clinical Project Delivery and Operational Excellence,* **Richmond Pharmacology**

10:30 Morning Coffee and Networking

11:00 PANEL DISCUSSION

MANAGING THROUGH DISRUPTION: HOW LEADERS SUSTAIN TEAM PERFORMANCE DURING CHANGE

- Organizational shifts in priority and how to keep teams aligned
- Maintaining productivity through departmental reorganizations and M&A
- Retaining knowledge during team turnover and leadership transitions
- Tools and frameworks that support resilience and continuity

Jortin George, *Regional Head UK& Europe,* **Cipla**
Jesse Gallagher, *Early Phase Risk & Compliance Lead II,* **Parexel**
Puja Myles- Director, *Clinical Practice Research Datalink,* **Medicines and Healthcare products Regulatory Agency**

PMO AND PORTFOLIO: FROM ONE-PERSON SHOP TO ENTERPRISE ENGINE

11:30 KEYNOTE

EARLY-PHASE PROJECT EVALUATION LEVERAGING KNOWLEDGE RESOURCES

A structured, knowledge-driven framework to evaluate innovator molecules and generic opportunities from early ideation onwards, supporting informed portfolio and project decisions well ahead of LoE. The approach integrates multiple validated internal and external data sources to ensure transparent, consistent, and cross-functional decision-making.

Objectives

- Introduce a generic mindset for early evaluation, recognizing that value creation starts many years before LoE
- Provide a structured 8-step framework to assess innovator molecules and generic feasibility in a consistent and reproducible way
- Demonstrate how to systematically use knowledge resources (public and subscription databases) to support early portfolio and pipeline decisions
- Strengthen cross-functional alignment by using common data, assumptions, and evaluation logic

Key takeaways

- Early generic project decisions must be evidence-based, not intuition-driven, and made long before market entry
- A holistic assessment requires combining commercial, medical, regulatory, IP, pricing, and competitive insights
- The 8-step framework covers:
  - Peak value estimation
  - Medical positioning within the treatment landscape
  - Product profile and formulation complexity
  - Ongoing and future clinical development
  - Patent landscape and IP risks
  - Innovator pricing across reference markets
  - Launch geography and entry strategy
  - Intensity and feasibility of generic competition

CONFERENCE AGENDA

DAY 2

- Using multiple sources (e.g., EvaluatePharma, IPD Analytics, Cortellis, PubMed, FDA/EMA, IQVIA, and internal Sandoz data) improves robustness, transparency, and confidence in recommendations
- The framework supports better prioritization, early risk identification, and more informed go/no-go decisions

Bahadir Cakmak, *Director- Early Portfolio and Pipeline,* **Sandoz**

12:00 **KEYNOTE**

PMO MATURITY IN THE REAL WORLD: WHAT WORKS AT EACH STAGE

Leaders from companies at three stages of PMO maturity compare how they guide work, run governance, and connect to portfolio decisions. You will hear how a one person PMO, an enabling PMO, and an enterprise PMO each create clarity without bureaucracy.

- **One person PMO:** what to provide first for Clinical, Regulatory, CMC, and Finance, and what to postpone.
- **Enabling PMO:** services that lift delivery across programs, such as decision logs, common templates, and training, and how they plug into portfolio reviews.
- **Enterprise PMO:** how portfolio management sets priorities, allocates resources, and measures benefits, and how the PMO enforces decision rights.
- **Moving up the ladder:** triggers to scale, warning signs you are over built or under built, and how to phase capabilities.
- **People and sponsorship:** what executives must do, how to earn buy in from project managers, and how to keep the culture focused on predictable execution.

Samantha Larner, *Programme Delivery Manager,* **Medicines and Healthcare products Regulatory Agency**

12:30 **Networking Luncheon**

13:30 **WORKSHOPS**

WORKSHOP 1: COST TO GATE AND COST TO LAUNCH LAB

Turn scope into a defendable budget and variance view.

- Use parametric and analogous estimating to build the first cut
- Add country and monitoring scenarios and protocol amendment impact
- Build a change order impact log and estimate at completion
- Prepare a governance slide that explains variance and options

Take home: a reusable cost model and change order ledger

James Rickard, *Chief Scientific Officer,* **Richmond Research Institute**

WORKSHOP 2: THE HUMAN SIDE OF HIGH-PERFORMANCE TEAMS

Practical methods to build trust, shared mindset, and accountability.

- Self-assess current team dynamics; define meeting norms.
- Conflict resolution drills and rapid decision practice.
- Write a simple escalation ladder with roles (RACI).

Take-home: a "team improvement plan" you can run next week.

Patrick Ramiah, *Director of Clinical Project Delivery and Operational Excellence,* **Richmond Pharmacology**

WORKSHOP 3: DIGITAL HEALTH-CHECK AND TEAM ANALYTICS TOOLS

Use data to continuously measure and improve team performance.

- Design a lightweight health-check (qual + quant).
- Build a team dashboard (decision latency, action completion, meeting load).
- Define weekly cadence and ownership for updates.

Take-home: dashboard mock-up and data-collection template.

George Havers, *Director,* **Trialmed**

14:30 **ROUNDTABLES**

ROUNDTABLE 1: MANAGING TEAM TRANSITIONS AND LEADERSHIP HANDOVER WITHOUT LOSING MOMENTUM

Exploring best practices for knowledge transfer, leadership changeovers, and maintaining continuity.

- How do you preserve trust and rhythm when leadership changes mid-project?
- What tools or rituals help build fast credibility for a new PM?
- How to measure team confidence post-handover?

Jignesh Rathod, *Senior Director and Head of Project Management - Europe,* **Parexel**

ROUNDTABLE 2: DEALING WITH UNDERPERFORMANCE AND RESTORING COLLECTIVE TALENT

Building strategies to address motivation, capability, and bandwidth issues

- How can project leaders diagnose the real cause of underperformance?
- What's the right balance between coaching and escalation?
- How to maintain team morale when addressing individual performance issues?

Patrick Kamba, *Executive Director, Project Management,* **PPD, Thermofisher Scientific**

15:30 **Afternoon Coffee and Networking**

16:00 **The End of the Conference**

OUR VALUED PARTNERS, PAST AND PRESENT

WHY? SUMMITS

CONTACT US

GENERAL INQUIRIES:

Liza Zhaivoronok
Vice President, PPM World Tour
liza.zhaivoronok@whysummits.com

SPEAKING:

Barbora Kačmarčíková
Conference Producer
barbora.kacmarcikova@whysummits.com

Tania Jadhav
Conference Producer
tania.jadhav@whysummits.com

ATTENDING AND SPONSORING:

Lubos Kusy
Director of PPM & PV Projects
lubos@whysummits.com

Srihari Kamban
Sponsorship Director
shk@whysummits.com

FOR THE 2026 SPONSOR KIT:

why@whysummits.com

whysummits.com/partnership-exhibitopportunities/

JOIN US IN LONDON

The industries that shape the future will be in the room.
Make sure your brand is part of the conversation.

Please note – all of the information in this document is subject to change at any time. Whilst every effort has been made to ensure the accuracy of the information, statements and decisions recorded in them, their status will remain that of a draft until such time as they are confirmed as a final version prior the subsequent meeting. Additionally, the user information is only valid at a certain moment in time and is subject to change due to movement and changes in bit rate requirements.